Fairvalue-Calculator Fairvalue-Calculator
EN DE

Emmaus Life Sciences, Inc (EMMA) Fair Value & Analysis

Healthcare · US · Market cap $674K

Price$0.0100
Fair Value$0.0110
Upside+10.0%
Quality95/100
Evidence: Low Range $0.0110 – $0.0110

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Emmaus Life Sciences, Inc (EMMA) currently trades at $0.0100, while our model-based Fair Value estimate is $0.0110 — implying the stock looks roughly 10.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Emmaus Life Sciences, Inc (EMMA) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.0110 versus a price of $0.0100 — about +10% (undervalued). Model-based estimate, not financial advice.
What is the fair value of EMMA?
Our 21-model fair value for Emmaus Life Sciences, Inc is $0.0110 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.0100.
What is the quality score of EMMA?
Emmaus Life Sciences, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.